

## Reference List – Chapter 07

- Araki, T., Y. Sasaki, and J. Milbrandt. 2004. Increased Nuclear Nad Biosynthesis and Sirt1 Activation Prevent Axonal Degeneration. *Science* **305**(5686):1010–1013. [07]
- Atwal, J. K., Y. Chen, C. Chiu, et al. 2011. A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-Beta Production *in Vivo*. *Sci. Transl. Med.* **3**(84):84ra43. [07]
- Ayutyanont, N., J. B. Langbaum, S. B. Hendrix, et al. 2014. The Alzheimer's Prevention Initiative Composite Cognitive Test Score: Sample Size Estimates for the Evaluation of Preclinical Alzheimer's Disease Treatments in Presenilin 1 E280a Mutation Carriers. *J. Clin. Psychiatry* **75**(6):652–660. [07]
- Bartus, R. T., M. S. Weinberg, and R. J. Samulski. 2014. Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy. *Mol Ther* **22**(3):487–497. [07]
- Bateman, R. J., C. Xiong, T. L. Benzinger, et al. 2012. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. *N. Engl. J. Med.* **367**(9):795–804. [07]
- Benilova, I., E. Karran, and B. De Strooper. 2012. The Toxic Abeta Oligomer and Alzheimer's Disease: An Emperor in Need of Clothes. *Nat. Neurosci.* **15**(3):349–357. [07]
- Berk, J. L., O. B. Suhr, L. Obici, et al. 2013. Repurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial. *JAMA* **310**(24):2658–2667. [07]
- Bertram, L., C. Lange, K. Mullin, et al. 2008. Genome-Wide Association Analysis Reveals Putative Alzheimer's Disease Susceptibility Loci in Addition to APOE. *Am. J. Hum. Genet.* **83**(5):623–632. [07]
- Bien-Ly, N., A. K. Gillespie, D. Walker, S. Y. Yoon, and Y. Huang. 2012. Reducing Human Apolipoprotein E Levels Attenuates Age-Dependent Abeta Accumulation in Mutant Human Amyloid Precursor Protein Transgenic Mice. *J. Neurosci.* **32**(14):4803–4811. [07]
- Biglan, K. M., Y. Zhang, J. D. Long, et al. 2013. Refining the Diagnosis of Huntington Disease: The PREDICT-HD Study. *Front. Aging Neurosci.* **5**:12. [07]
- Birks, J. 2006. Cholinesterase Inhibitors for Alzheimer's Disease. *Cochrane Database Syst. Rev.*(1):CD005593. [07]
- Boutajangout, A., J. Ingadottir, P. Davies, and E. M. Sigurdsson. 2011. Passive Immunization Targeting Pathological Phospho-Tau Protein in a Mouse Model Reduces Functional Decline and Clears Tau Aggregates from the Brain. *J. Neurochem.* **118**(4):658–667. [07]
- Caughey, B., and P. T. Lansbury. 2003. Protofibrils, Pores, Fibrils, and Neurodegeneration: Separating the Responsible Protein Aggregates from the Innocent Bystanders. *Annu. Rev. Neurosci.* **26**:267–298. [07]
- Cenik, B., C. F. Sephton, B. Kutluk Cenik, J. Herz, and G. Yu. 2012. Progranulin: A Proteolytically Processed Protein at the Crossroads of Inflammation and Neurodegeneration. *J. Biol. Chem.* **287**(39):32298–32306. [07]
- Chaudhuri, K. R., D. G. Healy, and A. H. Schapira. 2006. Non-Motor Symptoms of Parkinson's Disease: Diagnosis and Management. *Lancet Neurol.* **5**(3):235–245. [07]
- Chen, H. K., Z. Liu, A. Meyer-Franke, et al. 2012. Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons. *J. Biol. Chem.* **287**(8):5253–5266. [07]
- Coelho, T., L. F. Maia, A. Martins da Silva, et al. 2012. Tafamidis for Transthyretin Familial Amyloid Polyneuropathy: A Randomized, Controlled Trial. *Neurology* **79**(8):785–792. [07]
- Cramer, P. E., J. R. Cirrito, D. W. Wesson, et al. 2012. Apoe-Directed Therapeutics Rapidly Clear Beta-Amyloid and Reverse Deficits in AD Mouse Models. *Science* **335**(6075):1503–1506. [07]
- Demeule, M., J. C. Currie, Y. Bertrand, et al. 2008. Involvement of the Low-Density Lipoprotein Receptor-Related Protein in the Transcytosis of the Brain Delivery Vector Angiopep-2. *J. Neurochem.* **106**(4):1534–1544. [07]
- Dodart, J. C., R. A. Marr, M. Koistinaho, et al. 2005. Gene Delivery of Human Apolipoprotein E Alters Brain Abeta Burden in a Mouse Model of Alzheimer's Disease. *PNAS* **102**(4):1211–1216. [07]
- Fagan, A. M., M. A. Mintun, R. H. Mach, et al. 2006. Inverse Relation between *in Vivo* Amyloid Imaging Load and Cerebrospinal Fluid Abeta42 in Humans. *Ann. Neurol.* **59**(3):512–519. [07]
- Fernandez, F., W. Morishita, E. Zuniga, et al. 2007. Pharmacotherapy for Cognitive Impairment in a Mouse Model of Down Syndrome. *Nat. Neurosci.* **10**(4):411–413. [07]
- Frost, B., and M. I. Diamond. 2010. Prion-Like Mechanisms in Neurodegenerative Diseases. *Nat. Rev. Neurosci.* **11**(3):155–159. [07]
- Greicius, M. D., G. Srivastava, A. L. Reiss, and V. Menon. 2004. Default-Mode Network Activity Distinguishes Alzheimer's Disease from Healthy Aging: Evidence from Functional MRI. *PNAS* **101**(13):4637–4642. [07]
- Guerreiro, R., A. Wojtas, J. Bras, et al. 2013. TREM2 Variants in Alzheimer's Disease. *N. Engl. J. Med.* **368**(2):117–127. [07]
- Haqqani, A. S., N. Caram-Salas, W. Ding, et al. 2013. Multiplexed Evaluation of Serum and CSF Pharmacokinetics of Brain-Targeting Single-Domain Antibodies Using a NanoLC-SRM-ILIS Method. *Molec. Pharm.* **10**(5):1542–1556. [07]
- Hayden, E. Y., and D. B. Teplow. 2013. Amyloid Beta-Protein Oligomers and Alzheimer's Disease. *Alzheimers Res. Ther.* **5**(6):60. [07]
- Heiman, M., A. Schaefer, S. Gong, et al. 2008. A Translational Profiling Approach for the Molecular Characterization of CNS Cell Types. *Cell* **135**(4):738–748. [07]

**Reference list for Chapter 7.** From: “Translational Neuroscience: Toward New Therapies,” Karoly Nikolich and Steven E. Hyman, eds. 2015. Strüngmann Forum Reports, vol. 17, series ed. J. Lupp. Cambridge, MA: MIT Press. ISBN 978-0-262-02986-5.

- Heneka, M. T., M. P. Kummer, A. Stutz, et al. 2013. Nlrp3 Is Activated in Alzheimer's Disease and Contributes to Pathology in APP/PS1 Mice. *Nature* **493(7434)**:674–678. [07]
- Hollingworth, P., D. Harold, R. Sims, et al. 2011. Common Variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP Are Associated with Alzheimer's Disease. *Nat. Genet.* **43(5)**:429–435. [07]
- Holtzman, D. M., J. Herz, and G. Bu. 2012. Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease. *Cold Spring Harb. Perspect. Med.* **2(3)**:a006312. [07]
- Holtzman, D. M., J. C. Morris, and A. M. Goate. 2011. Alzheimer's Disease: The Challenge of the Second Century. *Sci. Transl. Med.* **3(77)**:77sr71. [06, 07]
- Hudry, E., J. Dashkoff, A. D. Roe, et al. 2013. Gene Transfer of Human *ApoE* Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain. *Sci. Transl. Med.* **5(212)**:212ra161. [07]
- Hurd, M. D., P. Martorell, A. Delavande, K. J. Mullen, and K. M. Langa. 2013. Monetary Costs of Dementia in the United States. *N. Engl. J. Med.* **368**:1326–1334. [01, 07]
- Iadecola, C. 2004. Neurovascular Regulation in the Normal Brain and in Alzheimer's Disease. *Nature Neurosci.* **5**:347–360. [07]
- Iiliff, J. J., M. Wang, Y. Liao, et al. 2012. A Paravascular Pathway Facilitates CSF Flow through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid  $\beta$ . *Sci. Transl. Med.* **4(147)**:147ra111. [07]
- Jack, C. R., Jr., and D. M. Holtzman. 2013. Biomarker Modeling of Alzheimer's Disease. *Neuron* **80(6)**:1347–1358. [07, 14]
- Jonsson, T., J. K. Atwal, S. Steinberg, et al. 2012. A Mutation in APP Protects against Alzheimer's Disease and Age-Related Cognitive Decline. *Nature* **488(7409)**:96–99. [07]
- Jonsson, T., H. Stefansson, S. Steinberg, et al. 2013. Variant of TREM2 Associated with the Risk of Alzheimer's Disease. *N. Engl. J. Med.* **368(2)**:107–116. [07]
- Ju, Y. E., B. P. Lucey, and D. M. Holtzman. 2014. Sleep and Alzheimer Disease Pathology: A Bidirectional Relationship. *Nat. Rev. Neurol.* **10(2)**:115–119. [07]
- Kim, J., J. M. Basak, and D. M. Holtzman. 2009. The Role of Apolipoprotein E in Alzheimer's Disease. *Neuron* **63(3)**:287–303. [07]
- Kim, J., A. E. Eltorai, H. Jiang, et al. 2012. Anti-apoE Immunotherapy Inhibits Amyloid Accumulation in a Transgenic Mouse Model of A $\beta$  Amyloidosis. *J. Exp. Med.* **209(12)**:2149–2156. [07]
- Kim, J., H. Jiang, S. Park, et al. 2011. Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-Beta Amyloidosis. *J. Neurosci.* **31(49)**:18007–18012. [07]
- Klunk, W. E., H. Engler, A. Nordberg, et al. 2004. Imaging Brain Amyloid in Alzheimer's Disease with Pittsburgh Compound-B. *Ann. Neurol.* **55(3)**:306–319. [07]
- Koldamova, R., N. F. Fitz, and I. Lefterov. 2010. The Role of ATP-Binding Cassette Transporter A1 in Alzheimer's Disease and Neurodegeneration. *Biochim. Biophys. Acta* **1801(8)**:824–830. [07]
- Krabbe, G., A. Halle, V. Matyash, et al. 2013. Functional Impairment of Microglia Coincides with Beta-Amyloid Deposition in Mice with Alzheimer-Like Pathology. *PLoS One* **8(4)**:e60921. [07]
- Lang, A. E., S. Gill, N. K. Patel, et al. 2006. Randomized Controlled Trial of Intraputamenal Glial Cell Line-Derived Neurotrophic Factor Infusion in Parkinson Disease. *Ann. Neurol.* **59(3)**:459–466. [07]
- Lee, H.-J., E.-J. Bae, and S.-J. Lee. 2014. Extracellular [Alpha]-Synuclein: A Novel and Crucial Factor in Lewy Body Diseases. *Nat. Rev. Neurol.* **10(2)**:92–98. [07]
- Mahley, R. W., and Y. Huang. 2012. Apolipoprotein E Sets the Stage: Response to Injury Triggers Neuropathology. *Neuron* **76(5)**:871–885. [07]
- Mandelkow, E. M., and E. Mandelkow. 2012. Biochemistry and Cell Biology of Tau Protein in Neurofibrillary Degeneration. *Cold Spring Harb. Perspect. Med.* **2(7)**:a006247. [07]
- Maruyama, M., H. Shimada, T. Suhara, et al. 2013. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls. *Neuron* **79(6)**:1094–1108. [07]
- Maslah, E., E. Rockenstein, I. Veinbergs, et al. 2001. Beta-Amyloid Peptides Enhance Alpha-Synuclein Accumulation and Neuronal Deficits in a Transgenic Mouse Model Linking Alzheimer's Disease and Parkinson's Disease. *PNAS* **98(21)**:12245–12250. [07]
- Mendell, J. T., and E. N. Olson. 2012. MicromRNAs in Stress Signaling and Human Disease. *Cell* **148(6)**:1172–1187. [07]
- Meyer-Luehmann, M., T. L. Spires-Jones, C. Prada, et al. 2008. Rapid Appearance and Local Toxicity of Amyloid-Beta Plaques in a Mouse Model of Alzheimer's Disease. *Nature* **451(7179)**:720–724. [07]
- Miller, T. M., A. Pestronk, W. David, et al. 2013. An Antisense Oligonucleotide against SOD1 Delivered Intrathecally for Patients with SOD1 Familial Amyotrophic Lateral Sclerosis: A Phase 1, Randomised, First-in-Man Study. *Lancet Neurol.* **12(5)**:435–442. [07]
- Moulder, K. L., B. J. Snider, S. L. Mills, et al. 2013. Dominantly Inherited Alzheimer Network: Facilitating Research and Clinical Trials. *Alzheimers Res. Ther.* **5(5)**:48. [07]
- Musiek, E. S., and D. M. Holtzman. 2012. Origins of Alzheimer's Disease: Reconciling Cerebrospinal Fluid Biomarker and Neuropathology Data Regarding the Temporal Sequence of Amyloid-Beta and Tau Involvement. *Curr. Opin. Neurobiol.* **25(6)**:715–720. [07]

**Reference list for Chapter 7.** From: “Translational Neuroscience: Toward New Therapies,” Karoly Nikolich and Steven E. Hyman, eds. 2015. Strüngmann Forum Reports, vol. 17, series ed. J. Lupp. Cambridge, MA: MIT Press. ISBN 978-0-262-02986-5.

- Naj, A. C., G. Jun, G. W. Beecham, et al. 2011. Common Variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 Are Associated with Late-Onset Alzheimer's Disease. *Nat. Genet.* **43(5)**:436–441. [07]
- Niewoehner, J., B. Bohrmann, L. Collin, et al. 2014. Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle. *Neuron* **81(1)**:49–60. [07]
- Obiano, O., and K. Ye. 2013. Novel Small Molecule Activators of the Trk Family of Receptor Tyrosine Kinases. *Biochim. Biophys. Acta* **1834(10)**:2213–2218. [07]
- Perry, D. C., and B. L. Miller. 2013. Frontotemporal Dementia. *Semin. Neurol.* **33(4)**:336–341. [07]
- Prinz, M., J. Priller, S. S. Sisodia, and R. M. Ransohoff. 2011. Heterogeneity of CNS Myeloid Cells and Their Roles in Neurodegeneration. *Nat. Neurosci.* **14(10)**:1227–1235. [07]
- Rafii, M. S., T. L. Baumann, R. A. Bakay, et al. 2014. A Phase I Study of Stereotactic Gene Delivery of AAV2-NGF for Alzheimer's Disease. *Alzheimers Dement.* [07]
- Salloway, S., R. Sperling, and H. R. Brashear. 2014. Phase 3 Trials of Solanezumab and Bapineuzumab for Alzheimer's Disease. *N. Engl. J. Med.* **370(15)**:1460. [07]
- Sanchez, P. E., L. Zhu, L. Verret, et al. 2012. Levetiracetam Suppresses Neuronal Network Dysfunction and Reverses Synaptic and Cognitive Deficits in an Alzheimer's Disease Model. *PNAS* **109(42)**:E2895–2903. [07]
- Schafer, D. P., E. K. Lehrman, A. G. Kautzman, et al. 2012. Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. *Neuron* **74(4)**:691–705. [07]
- Schrijvers, E. M., B. F. Verhaaren, P. J. Koudstaal, et al. 2012. Is Dementia Incidence Declining?: Trends in Dementia Incidence since 1990 in the Rotterdam Study. *Neurology* **78(19)**:1456–1463. [07]
- Shao, K., R. Huang, J. Li, et al. 2010. Angiopep-2 Modified PE-PEG Based Polymeric Micelles for Amphotericin B Delivery Targeted to the Brain. *J. Control Release* **147(1)**:118–126. [07]
- Spencer, B., R. A. Marr, R. Gindi, et al. 2011. Peripheral Delivery of a CNS Targeted, Metallo-Protease Reduces Abeta Toxicity in a Mouse Model of Alzheimer's Disease. *PLoS One* **6(1)**:e16575. [07]
- Sperling, R. A., P. S. Aisen, L. A. Beckett, et al. 2011. Toward Defining the Preclinical Stages of Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. *Alzheimers Dement.* **7(3)**:280–292. [07]
- Stein, T. D., V. E. Alvarez, and A. C. McKee. 2014. Chronic Traumatic Encephalopathy: A Spectrum of Neuropathological Changes Following Repetitive Brain Trauma in Athletes and Military Personnel. *Alzheimers Res. Ther.* **6(1)**:4. [07]
- Strittmatter, W. J., and A. D. Roses. 1996. Apolipoprotein E and Alzheimer's Disease. *Annu. Rev. Neurosci.* **19**:53–77. [07]
- Tremblay, M. E., and A. K. Majewska. 2011. A Role for Microglia in Synaptic Plasticity? *Commun. Integr. Biol.* **4(2)**:220–222. [07]
- Van Essen, D. C., S. M. Smith, D. M. Barch, et al. 2013. The WU-Minn Human Connectome Project: An Overview. *Neuroimage* **80**:62–79. [07]
- Varrone, A., and C. Halldin. 2012. New Developments of Dopaminergic Imaging in Parkinson's Disease. *Q. J. Nucl. Med. Mol. Imaging* [07]
- Wang, D., S. S. El-Amouri, M. Dai, et al. 2013. Engineering a Lysosomal Enzyme with a Derivative of Receptor-Binding Domain of Apoe Enables Delivery across the Blood-Brain Barrier. *PNAS* **110(8)**:2999–3004. [07]
- Wang, P., Y. Xue, X. Shang, and Y. Liu. 2010. Diphtheria Toxin Mutant CRM197-Mediated Transcytosis across Blood-Brain Barrier *in vitro*. *Cell. Mol. Neurobiol.* **30(5)**:717–725. [07]
- Wolf, A. B., J. Valla, G. Bu, et al. 2013. Apolipoprotein E as a Beta-Amyloid-Independent Factor in Alzheimer's Disease. *Alzheimers Res. Ther.* **5(5)**:38. [07]
- Xia, C. F., J. Arteaga, G. Chen, et al. 2013. [(18)F]T807, a Novel Tau Positron Emission Tomography Imaging Agent for Alzheimer's Disease. *Alzheimers Dement.* **9(6)**:666–676. [07]
- Yanamandra, K., N. Kfoury, H. Jiang, et al. 2013. Anti-Tau Antibodies That Block Tau Aggregate Seeding *in Vitro* Markedly Decrease Pathology and Improve Cognition *in Vivo*. *Neuron* **80(2)**:402–414. [07]
- Zlokovic, B. V. 2008. The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders. *Neuron* **57(2)**:178–201. [07]

**Reference list for Chapter 7.** From: “Translational Neuroscience: Toward New Therapies,” Karoly Nikolich and Steven E. Hyman, eds. 2015. Strüngmann Forum Reports, vol. 17, series ed. J. Lupp. Cambridge, MA: MIT Press. ISBN 978-0-262-02986-5.